TY - JOUR
T1 - Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis
AU - Verstovsek, Srdan
AU - Kantarjian, Hagop
AU - Mesa, Ruben A.
AU - Pardanani, Animesh D.
AU - Cortes-Franco, Jorge
AU - Thomas, Deborah A.
AU - Estrov, Zeev
AU - Fridman, Jordan S.
AU - Bradley, Edward C.
AU - Erickson-Viitanen, Susan
AU - Vaddi, Kris
AU - Levy, Richard
AU - Tefferi, Ayalew
PY - 2010/9/16
Y1 - 2010/9/16
N2 - BACKGROUND: Myelofibrosis is a Philadelphia chromosome-negative myeloproliferative neoplasm associated with cytopenias, splenomegaly, poor quality of life, and shortened survival. About half of patients with myelofibrosis carry a gain-of-function mutation in the Janus kinase 2 gene (JAK2 V617F) that contributes to the pathophysiology of the disease. INCB018424 is a potent and selective Janus kinase 1 (JAK1) and JAK2 inhibitor. METHODS: We conducted a phase 1-2 trial of INCB018424 in patients with JAK2 V617F-posi t i ve or JAK2 V617F-negative primary myelofibrosis, post-essential thrombocythemia myelofibrosis, or post-polycythemia vera myelofibrosis. RESULTS: A total of 153 patients received INCB018424 for a median duration of more than 14.7 months. The initial dose-escalation phase established 25 mg twice daily or 100 mg once daily as maximum tolerated doses, on the basis of reversible thrombocytopenia. A dose-dependent suppression of phosphorylated signal transducer and activator of transcription 3 (STAT3), a marker of JAK signaling, was demonstrated in patients with wild-type JAK2 and in patients with the JAK2 V617F mutation. We studied additional doses and established that a 15-mg twice-daily starting dose, followed by individualized dose titration, was the most effective and safest dosing regimen. At this dose, 17 of 33 patients (52%) had a rapid objective response (≥50% reduction of splenomegaly) lasting for 12 months or more, and this therapy was associated with grade 3 or grade 4 adverse events (mainly myelosuppression) in less than 10% of patients. Patients with debilitating symptoms, including weight loss, fatigue, night sweats, and pruritus, had rapid improvement. Clinical benefits were associated with a marked diminution of levels of circulating inflammatory cytokines that are commonly elevated in myelofibrosis. CONCLUSIONS: INCB018424 was associated with marked and durable clinical benefits in patients with myelofibrosis for whom no approved therapies existed. (Funded by Incyte; ClinicalTrials.gov number, NCT00509899.)
AB - BACKGROUND: Myelofibrosis is a Philadelphia chromosome-negative myeloproliferative neoplasm associated with cytopenias, splenomegaly, poor quality of life, and shortened survival. About half of patients with myelofibrosis carry a gain-of-function mutation in the Janus kinase 2 gene (JAK2 V617F) that contributes to the pathophysiology of the disease. INCB018424 is a potent and selective Janus kinase 1 (JAK1) and JAK2 inhibitor. METHODS: We conducted a phase 1-2 trial of INCB018424 in patients with JAK2 V617F-posi t i ve or JAK2 V617F-negative primary myelofibrosis, post-essential thrombocythemia myelofibrosis, or post-polycythemia vera myelofibrosis. RESULTS: A total of 153 patients received INCB018424 for a median duration of more than 14.7 months. The initial dose-escalation phase established 25 mg twice daily or 100 mg once daily as maximum tolerated doses, on the basis of reversible thrombocytopenia. A dose-dependent suppression of phosphorylated signal transducer and activator of transcription 3 (STAT3), a marker of JAK signaling, was demonstrated in patients with wild-type JAK2 and in patients with the JAK2 V617F mutation. We studied additional doses and established that a 15-mg twice-daily starting dose, followed by individualized dose titration, was the most effective and safest dosing regimen. At this dose, 17 of 33 patients (52%) had a rapid objective response (≥50% reduction of splenomegaly) lasting for 12 months or more, and this therapy was associated with grade 3 or grade 4 adverse events (mainly myelosuppression) in less than 10% of patients. Patients with debilitating symptoms, including weight loss, fatigue, night sweats, and pruritus, had rapid improvement. Clinical benefits were associated with a marked diminution of levels of circulating inflammatory cytokines that are commonly elevated in myelofibrosis. CONCLUSIONS: INCB018424 was associated with marked and durable clinical benefits in patients with myelofibrosis for whom no approved therapies existed. (Funded by Incyte; ClinicalTrials.gov number, NCT00509899.)
UR - http://www.scopus.com/inward/record.url?scp=77956696835&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=77956696835&partnerID=8YFLogxK
U2 - 10.1056/NEJMoa1002028
DO - 10.1056/NEJMoa1002028
M3 - Article
C2 - 20843246
AN - SCOPUS:77956696835
SN - 0028-4793
VL - 363
SP - 1117
EP - 1127
JO - New England Journal of Medicine
JF - New England Journal of Medicine
IS - 12
ER -